Debabrata Konar

Dr. Debabrata Konar

orcid

Research Focus & Metrics

Representative Publications

View All Publications
30 September 2016 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
KKKapil Kumar
Kapil Kumar
Debabrata KonarDebabrata Konar
Debabrata Konar
SGSandeep Goyal
Sandeep Goyal
MGMukesh Gangar
Mukesh Gangar
MCMangilal Chouhan
Mangilal Chouhan
VNVipin A. Nair
Vipin A. Nair

8 January 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LTLucca Trachsel
Lucca Trachsel
Debabrata KonarDebabrata Konar
Debabrata Konar
JHJason D. Hillman
Jason D. Hillman
CDCullen L. G. Davidson
Cullen L. G. Davidson
BSBrent S. Sumerlin
Brent S. Sumerlin

1 September 2021 in Macromolecules
Verified
Journal Article
Closed access
ZMZhihui Miao
Zhihui Miao
Debabrata KonarDebabrata Konar
Debabrata Konar
BSBrent S. Sumerlin
Brent S. Sumerlin
AVAdam S. Veige
Adam S. Veige

20 May 2023 in Macromolecular Rapid Communications
Verified
Journal Article
Closed access
PDF file
DPDigvijayee Pal
Digvijayee Pal
Debabrata KonarDebabrata Konar
Debabrata Konar
BSBrent S. Sumerlin
Brent S. Sumerlin

9 August 2016 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
KKKapil Kumar
Kapil Kumar
Debabrata KonarDebabrata Konar
Debabrata Konar
SGSandeep Goyal
Sandeep Goyal
MGMukesh Gangar
Mukesh Gangar
MCMangilal Chouhan
Mangilal Chouhan
VNVipin A. Nair
Vipin A. Nair

1 January 2022 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Debabrata KonarDebabrata Konar
Debabrata Konar
SMSaurabh Maru
Saurabh Maru
SKSubhabrata Kar
Subhabrata Kar
KKKapil Kumar
Kapil Kumar
Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer. The past few years have seen a substantial increase in breast cancer awareness campaigns and active research in fields of diagnosis and targeted therapy. These factors have led to a better mechanistic understanding of the disease, detection at earlier stages, and a more personalized approach to treatment, ultimately causing a crucial increase in the survival rates after detection. However, with the advances in treatment, cases of patients developing primary resistance and acquired resistance are increasing. Most of the breast cancers which develop resistance to therapy are ER+ and are typically treated with tamoxifen and fulvestrant. These drugs either lower the levels of estrogen or inhibit the receptors for estrogen and prevent the tumor from spreading. Around one-third of women treated with these drugs develop resistance to them, lowering their chances of survival. This has directed the search for newer drug therapies to target advanced breast cancer and resistance. One of these efforts has resulted in the development of Palbociclib, a first in class inhibitor of cyclin dependent kinases 4 and 6 (CDK4 and CDK6), which was granted accelerated approval from the FDA for combination therapy in postmenopausal women with ER+, HER2- metastatic breast cancer. This review is focused on the various aspects of “Palbociclib” including its synthesis, molecular modeling studies, and efficacy and safety profile with data obtained from various clinical trials.